Aldeyra Therapeutics (ALDX) Income from Continuing Operations (2013 - 2026)
Aldeyra Therapeutics (ALDX) posted Income from Continuing Operations of 3452619.0 for Q1 2026, up 47.88% on a QoQ basis from 6624308.0 in Q4 2025, and up 80.38% year-over-year from 1914044.2 in Q1 2025.
Aldeyra Therapeutics (ALDX) Income from Continuing Operations (2013 - 2026) Analysis & Trends
Aldeyra Therapeutics' Income from Continuing Operations history runs 14 years deep, the most recent figure standing at 3452619.0 for Q1 2026.
- Quarterly Income from Continuing Operations rose 80.38% year-over-year to 3452619.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 34590045.0 (up 52.11% YoY) and the FY2025 annual result came in at 38548602.0, up 34.45% from the prior year.
- Income from Continuing Operations was 3452619.0 for Q1 2026 at Aldeyra Therapeutics, up from 6624308.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 3452619.0 in Q1 2026 and bottomed at 41499272.0 in Q1 2023.
- A 5-year average of 16019354.88 and a median of 15762529.0 in 2024 frame the typical range for Income from Continuing Operations.
- Peak annual rise in Income from Continuing Operations reached 80.52% in 2024, while the deepest fall reached 212.27% in 2024.
- Aldeyra Therapeutics' Income from Continuing Operations stood at 13153608.0 in 2022, then surged by 61.62% to 5047779.0 in 2023, then slumped by 212.27% to 15762529.0 in 2024, then surged by 57.97% to 6624308.0 in 2025, then soared by 47.88% to 3452619.0 in 2026.
- Business Quant data shows ALDX's Income from Continuing Operations at 3452619.0 in Q1 2026, 6624308.0 in Q4 2025, and 14024588.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,019.86 Bn | 66,019.58 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,909.20 Bn | 1,909.14 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 468.20 Bn | 463.41 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 122.50 Bn | 115.26 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 70.15 Bn | 61.39 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 55.58 Bn | 50.39 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Alnylam Pharmaceuticals | 37.43 Bn | 34.43 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Aldeyra Therapeutics | 93.19 Mn | 93.19 Mn | - | -3.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.45 Mn |
| Dec 31, 2025 | -6.62 Mn |
| Sep 30, 2025 | -14.02 Mn |
| Jun 30, 2025 | -10.49 Mn |
| Mar 31, 2025 | -17.60 Mn |
| Dec 31, 2024 | -15.76 Mn |
| Sep 30, 2024 | -22.02 Mn |
| Jun 30, 2024 | -16.85 Mn |
| Mar 31, 2024 | -8.08 Mn |
| Dec 31, 2023 | -5.05 Mn |
| Sep 30, 2023 | -15.18 Mn |
| Jun 30, 2023 | -25.96 Mn |
| Mar 31, 2023 | -41.50 Mn |
| Dec 31, 2022 | -13.15 Mn |
| Sep 30, 2022 | -19.03 Mn |
| Jun 30, 2022 | -18.97 Mn |
| Mar 31, 2022 | -18.58 Mn |
| Dec 31, 2021 | -16.07 Mn |
| Sep 30, 2021 | -27.38 Mn |
| Jun 30, 2021 | -35.84 Mn |